Campylobacter antimicrobial resistance in Peru: a ten-year observational study

BMC Infectious Diseases

Matthew Kasper⁸  Juan Perez⁸  Marieke Rosenbaum⁸  C Sofia Arriola¹  Franca Jones⁸  Eric Hall⁸  Ryan Maves⁸  Michael Gregory⁸  Drake Tilley⁸  Maruja Bernal⁸  Rina Meza⁸  Martín Casapia⁴  Carlos Calampa⁶  Eduardo Salazar-Lindo²  Nancy Chuquiray^1,10  Martha Lopez⁵  José Guevara³  Máximo Camiña⁷  Augusto Valencia⁹  Lilian Patiño^1,11  Rito Zerpa^1,11  Claudio Rocha⁸  Simon Pollett⁸ 

[1] Facultad de Medicina Veterinaria, Universidad de San Marcos, San Marcos, Peru;Laboratorio Gastrolab, Lima, Peru;Hospital Nacional Daniel A.Carrion, Lima, Peru;Hospital Regional, Iquitos, Peru;Laboratorio Servisalud, Cusco, Peru;Hospital Apoyo de Iquitos, Iquitos, Peru;Hospital de Emergencias Pediátricas, Lima, Peru;Bacteriology Department, U.S Naval Medical Research Unit-6 (NAMRU-6), Venezuela Ave, Block 36, Callao 2, Lima, Peru;Hospital Nacional Docente Madre-Niño, Lima, Peru;EsSalud Hospital Alberto Sabogal Sologuren, Lima, Peru;Instituto Nacional de Salud del Niño, Lima, Peru

关键词: Peru;    Macrolides;    Fluoroquinolones;    Antibiotic resistance;    Campylobacter;   

Others  :  1159715
DOI  :  10.1186/1471-2334-12-193

 received in 2011-12-20, accepted in 2012-06-19,  发布年份 2012

【 摘 要 】

Background

Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers’ diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.

Methods

Surveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608).

Results

Comparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).

Conclusions

These results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.

【 授权许可】

   
2012 Pollett et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Allos BM, Blaser MJ: Mandell, Douglas & Bennett's Principles and Practice of Infectious Diseases. 7th edition. Edited by Mandel GL. Philidelphia, PA: Elsevier Publishing Co; 2009. Chapter 216
• [2]Ochoa TJ, Ecker L, Barletta F, Mispireta ML, Gil AI, Contreras C, Molina M, Amemiya I, Verastegui H, Hall ER, Cleary TG, Lanata CF: Age-related susceptibility to infection with diarrheagenic Escherichia coli among infants from Periurban areas in Lima, Peru. Clin Infect Dis 2009, 49(11):1694-1702.
• [3]World Health Organization: The increasing incidence of human Campylobacteriosis. Copenhagen: Report and Proceedings of a WHO Consultation of Experts; 2001.
• [4]Shah N, DuPont HL, Ramsey DJ: Global etiology of travelers' diarrhea: systematic review from 1973 to the present. AmJTrop Med Hyg 2009, 80(4):609-614.
• [5]Luangtongkum T, Jeon B, Han J, Plummer P, Logue CM, Zhang Q: Antibiotic resistance in Campylobacter: emergence, transmission and persistence. Future Microbiol 2009, 4(2):189-200.
• [6]Moore JE, Barton MD, Blair IS, Corcoran D, Dooley JS, Fanning S, Kempf I, Lastovica AJ, Lowery CJ, Matsuda M, McDowell DA, McMahon A, Millar BC, Rao JR, Rooney PJ, Seal BS, Snelling WJ, Tolba O: The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect 2006, 8(7):1955-1966.
• [7]Payot S, Bolla JM, Corcoran D, Fanning S, Megraud F, Zhang Q: Mechanisms of fluoroquinolone and macrolide resistance in Campylobacter species. Microbes Infect 2006, 8(7):1967-1971.
• [8]Zhang M, Gu Y, He L, Ran L, Xia S, Han X, Li H, Zhou H, Cui Z, Zhang J: Molecular typing and antimicrobial susceptibility profiles of Campylobacter jejuni isolates from north China. J Med Microbiol 2010, 59(Pt 10):1171-1177.
• [9]Vicente A, Barros R, Florinda A, Silva A, Hanscheid T: High rates of fluoroquinolone-resistant Campylobacter in Portugal - need for surveillance. Euro Surveill 2008, 13(6):8031.
• [10]Nelson JM, Chiller TM, Powers JH, Angulo FJ: Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis 2007, 44(7):977-980.
• [11]Putnam SD, Frenck RW, Riddle MS, El-Gendy A, Taha NN, Pittner BT, Abu-Elyazeed R, Wierzba TF, Rao MR, Savarino SJ, Clemens JD: Antimicrobial susceptibility trends in Campylobacter jejuni and Campylobacter coli isolated from a rural Egyptian pediatric population with diarrhea. Diagn Microbiol Infect Dis 2003, 47(4):601-608.
• [12]Fernandez H: Campylobacter and campylobacteriosis: a view from South America. Rev Peru Med Exp Salud Publica 2011, 28(1):121-127.
• [13]Aquino MH, Filgueiras AL, Ferreira MC, Oliveira SS, Bastos MC, Tibana A: Antimicrobial resistance and plasmid profiles of Campylobacter jejuni and Campylobacter coli from human and animal sources. Lett Appl Microbiol 2002, 34(2):149-153.
• [14]Freedman DO: Infections in Returned Travellers. In Mandell, Douglas & Bennett's Principles and Practice of Infectious Diseases. 7th edition. Philidelphia, PA: Elsevier Publishing Co; 2009. Chapter 330
• [15]World Health Organization: Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae. Geneva: WHO Press; 2005.
• [16]Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, Johnson BP, Moore KA, Osterholm MT: Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med 1999, 340(20):1525-1532.
• [17]Engberg J, Neimann J, Nielsen EM, Aerestrup FM, Fussing V: Quinolone-resistant Campylobacter infections: risk factors and clinical consequences. Emerg Infect Dis 2004, 10(6):1056-1063.
• [18]Nacional C: Instituto Nacional de Estadistica e Informatica. Lima: Segundo Edicion; 2008.
• [19]Patrick RM, Baron EJ, Pfaller MA, Tenover FC, Yolken RH: Manual of Clinical Microbiology. 6th edition. 1995, 486-487.
• [20]CLSI: Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guidelines - 2nd Edition. CLSI document M45-A2. Wayne, PA: Clinical Laboratory and Standards Institute; 2010.
• [21]Vlieghe ER, Jacobs JA, Van Esbroeck M, Koole O, Van Gompel A: Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006. J Travel Med 2008, 15(6):419-425.
• [22]Fernandez H, Mansilla M, Gonzalez V: Antimicrobial susceptibility of Campylobacter jejuni subsp. jejuni assessed by E-test and double dilution agar method in Southern Chile. Mem Inst Oswaldo Cruz 2000, 95(2):247-249.
• [23]Serichantalergs O, Pootong P, Dalsgaard A, Bodhidatta L, Guerry P, Tribble DR, Anuras S, Mason CJ: PFGE, Lior serotype, and antimicrobial resistance patterns among Campylobacter jejuni isolated from travelers and US military personnel with acute diarrhea in Thailand, 1998-2003. Gut Pathog 2010, 2(1):15. BioMed Central Full Text
• [24]Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I: Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001, 7(1):24-34.
• [25]Ellis-Pegler RB, Hyman LK, Ingram RJ, McCarthy M: A placebo controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the community. J Antimicrob Chemother 1995, 36(1):259-263.
• [26]Llanos-Zavalaga F, Mayca Perez J, Contreras Rios C: [Characteristics of antibiotic prescription during office visits in the Hospital Cayetano Heredia in Lima, Peru]. Rev Esp Salud Publica 2002, 76(3):207-214.
• [27]Kalter HD, Gilman RH, Moulton LH, Cullotta AR, Cabrera L, Velapatino B: Risk factors for antibiotic-resistant Escherichia coli carriage in young children in Peru: community-based cross-sectional prevalence study. AmJTrop Med Hyg 2010, 82(5):879-888.
• [28]Kristiansson C, Reilly M, Gotuzzo E, Rodriguez H, Bartoloni A, Thorson A, Falkenberg T, Bartalesi F, Tomson G, Larsson M: Antibiotic use and health-seeking behaviour in an underprivileged area of Peru. Trop Med Int Health 2008, 13(3):434-441.
• [29]Gaunt PN, Piddock LJ: Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 1996, 37(4):747-757.
• [30]Smith JL, Fratamico PM: Fluoroquinolone resistance in campylobacter. J Food Prot 2010, 73(6):1141-1152.
• [31]Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones R, Nightingale C, Preston R, Waddell J: Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J Antimicrob Chemother 2004, 53(1):28-52.
• [32]Newell DG, Koopmans M, Verhoef L, Duizer E, Aidara-Kane A, Sprong H, Opsteegh M, Langelaar M, Threfall J, Scheutz F, van der Giessen J, Kruse H: Food-borne diseases - the challenges of 20 years ago still persist while new ones continue to emerge. Int J Food Microbiol 2010, 139(Suppl 1):S3-S15.
• [33]Phillips I: Withdrawal of growth-promoting antibiotics in Europe and its effects in relation to human health. Int J Antimicrob Agents 2007, 30(2):101-107.
• [34]Thakur S, Zhao S, McDermott PF, Harbottle H, Abbott J, English L, Gebreyes WA, White DG: Antimicrobial resistance, virulence, and genotypic profile comparison of Campylobacter jejuni and Campylobacter coli isolated from humans and retail meats. Foodborne Pathog Dis 2010, 7(7):835-844.
• [35]Lyhs U, Katzav M, Isohanni P, Heiska H, Maijala R: The temporal, PFGE and resistance pattern associations suggest that poultry products are only a minor source of human infections in western Finland. Food Microbiol 2010, 27(2):311-315.
• [36]Oberhelman RA, Gilman RH, Sheen P, Cordova J, Taylor DN, Zimic M, Meza R, Perez J, LeBron C, Cabrera L, Rodgers FG, Woodward DL, Price LJ: Campylobacter transmission in a Peruvian shantytown: a longitudinal study using strain typing of campylobacter isolates from chickens and humans in household clusters. J Infect Dis 2003, 187(2):260-269.
• [37]Mendoza AP, Maves R, Bernal M, Villena M, Brightsmith DJ, Montgomery J: Evidence of Antibiotic Resistant Bacterial Strains Circulating among Birds Sold in Live Markets of Peru, abstr. Atlanta, GA: International Conference on Emerging Infectious Diseases; 2010:184.
• [38]Kuana SL, dos Santos LR: Antimicrobial resistance in Campylobacter spp isolated from broiler flocks. Braz J Microbiol 2008, 39(4):738-740.
• [39]http://www.sunat.gob.pe/operatividadaduanera/index.html[cited 2012 May 10]
• [40]El Peruano – Normas Legales. Decreto Supremo N 015-98-AG: Reglamento de Registro, Control y Comercialización de Productos de Suo Veterinario y de Alimentos para Animales. Lima-Perú; 1998:162446-162452.
• [41]Garcia PC, Valenzuela NS, Rodriguez MV, Leon EC, Fernandez HJ: Antimicrobial susceptibility of Campylobacter jejuni isolates from stool cultures in Santiago, Chile. Rev Chilena Infectol 2009, 26(6):511-514.
• [42]Figueroa G, Troncoso M, Galeno H, Soto V, Toledo MS: Biotypes, serogroups and antibiotic susceptibility of Campylobacter jejuni and Campylobacter coli in Chile. J Infect 1990, 20(2):123-127.
• [43]Perez-Boto D, Lopez-Portoles JA, Simon C, Valdezate S, Echeita MA: Study of the molecular mechanisms involved in high-level macrolide resistance of Spanish Campylobacter jejuni and Campylobacter coli strains. J Antimicrob Chemother 2010, 65(10):2083-2088.
• [44]Belanger AE, Shryock TR: Macrolide-resistant Campylobacter: the meat of the matter. J Antimicrob Chemother 2007, 60(4):715-723.
• [45]Gibreel A, Taylor DE: Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 2006, 58(2):243-255.
• [46]Funke G, Baumann R, Penner JL, Altwegg M: Development of resistance to macrolide antibiotics in an AIDS patient treated with clarithromycin for Campylobacter jejuni diarrhea. Eur J Clin Microbiol Infect Dis 1994, 13(7):612-615.
• [47]Klena JD, Parker CT, Knibb K, Ibbitt JC, Devane PM, Horn ST, Miller WG, Konkel ME: Differentiation of Campylobacter coli, Campylobacter jejuni, Campylobacter lari, and Campylobacter upsaliensis by a multiplex PCR developed from the nucleotide sequence of the lipid A gene lpxA. J Clin Microbiol 2004, 42(12):5549-5557.
• [48]van der Beek MT, Claas EC, Mevius DJ, van Pelt W, Wagenaar JA, Kuijper EJ: Inaccuracy of routine susceptibility tests for detection of erythromycin resistance of Campylobacter jejuni and Campylobacter coli. Clin Microbiol Infect 2010, 16(1):51-56.
• [49]Lehtopolku M, Kotilainen P, Puukka P, Nakari UM, Siitonen A, Eerola E, Huovinen P, Hakanen AJ: Inaccuracy of the disk diffusion method compared with the agar dilution method for susceptibility testing of Campylobacter spp. J Clin Microbiol 2012, 50(1):52-56.